EPISODE · Apr 9, 2026 · 32 MIN
396: A new trick for old science, and biotech VCs' scrambled playbook
from The Readout Loud · host STAT
Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA? Adam is out, so Elaine and Allison dive into the latest news, including how China and artificial intelligence are straining biotech VC firms, in addition to more M&A. They also discuss how a cancelled Food and Drug Administration meeting led to a biotech’s demise. Plus, there’s new hope for an old theory on treating Duchenne muscular dystrophy. STAT reporter Jason Mast details the clinical testing underway.
What this episode covers
Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA? Adam is out, so Elaine and Allison dive into the latest news, including how China and artificial intelligence are straining biotech VC firms, in addition to more M&A. They also discuss how a cancelled Food and Drug Administration meeting led to a biotech’s demise. Plus, there’s new hope for an old theory on treating Duchenne muscular dystrophy. STAT reporter Jason Mast details the clinical testing underway.
NOW PLAYING
396: A new trick for old science, and biotech VCs' scrambled playbook
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m